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Abstract
HIV protease inhibitors (PIs) show antimalarial activity in vitro and in animals. Whether this translates into a clinical benefit in
HIV-infected patients residing in malaria-endemic regions is unknown. We studied the incidence of malaria, as defined by
blood smear positivity or a positive Plasmodium falciparum histidine-rich protein 2 antigen test, among 444 HIV-infected
women initiating antiretroviral treatment (ART) in the OCTANE trial (A5208; ClinicalTrials.gov: NCT00089505). Participants
were randomized to treatment with PI-containing vs. PI-sparing ART, and were followed prospectively for $48 weeks; 73%
also received cotrimoxazole prophylaxis. PI-containing treatment was not associated with protection against malaria in this
study population.
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Introduction
The majority of HIV-infected individuals live in malaria-
endemic regions, and available evidence suggests that the
interaction between HIV and malaria infection is complex,
synergistic and bidirectional. Reported effects include increased
HIV replication resulting from immune activation [1], increased
parasitaemia (likely due to attenuated malaria-specific immunity)
[2], and complex pharmacokinetic interactions between antiret-
roviral and antimalarial drugs [3,4]. Taken together these
interactions likely result in worse clinical outcomes for co-infected
patients [5,6].
HIV protease inhibitors (PIs) have moderate in vitro activity
against the two most important malaria parasites, Plasmodium
falciparum [7] and P. vivax [8], as well as in vivo activity against
rodent malaria parasites [9]. The antimalarial action of these
agents is not fully understood but is likely related to their inhibition
of malaria parasite aspartic proteases or plasmepsins [10]. In
addition to their antiretroviral activity, PIs have been reported to
affect CD36-mediated cytoadherence of Plasmodium falciparum-
infected erythrocytes [11]. These data suggest that PIs may afford
antimalarial protection in HIV-infected people residing in malaria
endemic regions. However, whether this activity translates into a
clinically relevant effect in endemic settings remains to be
determined.
To explore the effect of PI-based ART on HIV-infected people
residing in malaria-endemic regions of sub-Saharan Africa we
undertook a retrospective study examining the incidence of
malaria in a group of women enrolled in AACTG 5208 [12]. In
this analysis, records of clinical diagnoses of malaria were not
included as these may lack sensitivity by missing subclinical
infection (malaria parasitaemia without malaria symptoms), and
specificity, whereby non-specific febrile illnesses commonly
attributable to malaria may be caused by other conditions [13].
Instead we compared the incidence of malaria in women
randomized to start ART with either a PI-containing or a PI-
sparing regimen in the OCTANE (A5208), with malaria diagnoses
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defined by either slide-confirmed diagnoses or by confirming the
presence of circulating parasite antigen in stored blood samples.
Detection of P. falciparum histidine-rich protein two (HRP2) by
antigen-capture immunoassay forms the basis of most rapid
diagnostic tests for falciparum malaria. This water-soluble protein
is released into the circulation of individuals infected with P.
falciparum, and has been shown to persist in the circulation after
clinical symptoms of malaria have resolved and parasites have
been cleared from the circulation. It has been reported to remain
in the blood for 7 days following treatment in 62–99% of patients,
for 14 days in 35–98% of patients, and for 28 days in 27–92%
[14,15].
Methods
The OCTANE study (AACTG 5208) consisted of two
concurrent randomized trials; detailed methods and primary
results have been published [12]. In Trial 1 (N= 243), women who
had previously received single-dose nevirapine (NVP) were
studied, whereas Trial 2 participants were women with no history
of NVP exposure (N= 502). In both trials, women were
randomized 1:1 (stratified by screening CD4+ cell count: ,50
cells/mL or $50 cells/mL) to receive either ritonavir-boosted
lopinavir (LPV/r)-based ART or nevirapine (NVP) -based ART.
All participants also received tenofovir disoproxil fumarate and
emtricitabine. Participants visited study sites at regular intervals (0,
4, 8, 12, 16, and 24 weeks; then every 12 weeks) for health
assessments that included collection and storage of venous blood,
and were followed for at least 48 weeks. The protocol and consents
were approved by IRBs at each site, and each participant provided
written informed consent.
The current study includes data obtained from participants
enrolled at the six OCTANE study sites where malaria
transmission has been reported to occur (Eldoret, Kenya, Kericho,
Kenya; Lilongwe, Malawi; Kampala, Uganda; Lusaka, Zambia;
and Harare, Zimbabwe). Study subjects were considered to have
malaria if they had a positive blood smear, a positive malaria rapid
diagnostic test (RDT), or if malaria antigen (P. falciparum Histidine-
rich protein 2 [HRP2]) was detected in the plasma samples that
were collected at study visits. All available samples from each
participant at the relevant sites were tested for HRP2 antigenemia
using a commercially available ELISA kit (Standard Diagnostics,
SD malaria Antigen Pf ELISA). Each plasma sample was tested in
duplicate as stated in the manufacturer’s instructions with positive
and negative controls on every plate. Evaluation of this kit before
the study indicated that it was more sensitive than other
commercially available plate-based HRP2 ELISA kits and was
between 30 and 120 fold more sensitive than malaria rapid
diagnostic kits (data not shown).
As malaria was not detected in two of the study sites and some
participants changed ART regimen and/or received cotrimox-
azole, a drug with known prophylactic activity against malaria in
HIV-infected populations [16], in a non-uniform fashion during
the study, data were analyzed on a cross-sectional basis and
stratified by treatment arm and cotrimoxazole use at the time of
sample collection. To avoid counting two sequential samples from
the same infected patient as two episodes, positive tests from a
single patient were counted as single episodes unless they were
separated by a negative sample. Data were tested for statistical
significance using a chi-squared test (http://www.openepi.com).
Multivariate analyses were not performed given the small numbers
of samples with a confirmed diagnosis of malaria.
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Results
HRP2 antigenemia was assessed by examining available plasma
samples totaling 3,516 from 444 women. All available samples
where a diagnosis of malaria had been made by blood smear, on-
site rapid diagnostic test or HRP2 ELISA where also tested for
malaria in our laboratory using immunochromatographic rapid
diagnostic tests (RDTs; First Response; Premier Medical Corpo-
ration Limited and First Sign ParaView; Unimed). An additional
113 samples from these 444 women were tested for malaria during
the original study (on site blood smear or RDT). As blood smear
slides were not retained these diagnoses could not be revalidated.
Therefore, laboratory data for malaria were available from a total
of 3629 samples from 444 subjects (1985 samples from women in
the LPV/r arm and 1644 from the NVP arm, Table 1).
P. falciparum infection was confirmed in 104 (2.9%) of the 3629
samples tested (Table 1), 34 by on-site blood smear or RDT, and
71 by HRP2 antigenemia. Only ten of the positive on-site samples
were available for retrospective testing for HRP2 antigen, one of
which tested positive. All samples that tested positive with RDTs
also tested positive for HRP2 by ELISA. No confirmed cases of
malaria were identified at the Harare (Zimbabwe) or Eldoret
(Kenya) sites (table 1). Subsequent analysis was therefore restricted
to the four sites where confirmed diagnoses were made (Table 2).
A total of 2,388 samples were tested from 265 women enrolled at
these four sites, among whom 53 (20%) had one or more episode
of confirmed malaria over the course of the study. The proportion
of samples positive for malaria was low, with 104 positive tests
(4.6% of samples). The distribution of these positive tests varied
widely across the four study sites (Lilongwe, 23/641 (3.6%);
Kampala 4/524 (0.8%); Kericho 7/563 (1.2%); Lusaka 70/773
(9.0%). A greater proportion of samples taken from subjects
receiving LPV/r-based ART were positive for malaria compared
to samples taken from subjects receiving vs. NVP-based ART
although the difference was not statistically significant (2.8%
compared to 1.8%, respectively, p = 0.13; Table 2A).
Consistent with standard management guidelines for patients
infected with HIV, the majority (81%) of study subjects were
taking daily cotrimoxazole prophylaxis at the time of blood
sampling (Table 1). While the incidence of malaria (allowing only
one episode of malaria per subject; 2.9% versus 2.2%; Table 2A)
and the number of episodes of malaria (allowing for multiple
episodes per patient only if separated by a negative sample; 3.6%
versus 2.4%; Table 2B) were slightly higher among subjects not
taking cotrimoxazole prophylaxis at the time of blood sampling,
this was not significant (P = 0.42 and P= 0.14 respectively). When
the combined effect of cotrimoxazole therapy and the antiretro-
viral regimen was examined, the incidence of malaria was lowest
among samples drawn from subjects taking cotrimoxazole and
NVP-based ART (1.7%; Table 2A) compared to those drawn from
patients taking cotrimoxazole and LPV/r-based ART (2.7%).
Subjects not taking cotrimoxazole also had a higher incidence of
malaria when taking LPV/r-based ART (3.3%) than those
subjects taking NVP-based ART (2.4%). None of these differences
were significant (P = 0.39).
Discussion
In this study, we observed a low incidence of malaria as defined
by positive malaria smears, RDTs, and antigenemia, and did not
find that PI-based ART was associated with a lower incidence of
malaria. Fifty three (20%) of the women in the study had at least
one episode of laboratory-confirmed malaria over the study
interval, 34 (64%) of these women were receiving PI-based ART at
the time of malaria diagnosis (Table 2A).
Although the results indicate that PI therapy did not exert a
protective effect against malaria in this population, a number of
circumstances that may have masked a protective effect should be
considered. In the first instance, it is possible that the low numbers
of malaria diagnosis made in our cohort underpowered the study
and prevented the identification of a protective effect. While this
study was predicted to have sufficient power to answer our
question when it was first designed, there was a significant
reduction in the prevalence of malaria in many parts of Africa in
the interval between design and study execution [16]. An
additional analysis where the incidence of malaria in this study
population was defined on clinical grounds rather than using a
more rigorous definition requiring a laboratory confirmed
diagnosis was in agreement with results reported here (manuscript
submitted).
The high rate of cotrimoxazole prophylaxis (80%) observed in
our study population, an intervention with a protective effect
Table 2. Malaria diagnoses made at the four sites where malaria was detected by blood smear (on-site testing), RDT (on-site
testing) or Pf Histidine-rich Protein-2 (PfHRP2) antigenemia.
A B
# (%) of patients with at least one episode of malaria
(N=2268 samples from 265 patients)
Episodes of malaria
(N=2462 samples from 265 patients)
PI-ART PI-ART
Yes
1221
No
1047
Yes
1342
No
1120
Cotrimoxazole Cotrimoxazole
Yes
1007
No
214
Yes
843
No
204
Yes
1095
No
247
Yes
899
No
221
Malaria Malaria
#27
(2.7%)
#7
(3.3%)
#14
(1.7%)
#5
(2.4%)
#33
(3.0%)
#11
(4.4%)
#15
(1.7%)
#6
(2.7%)
A) ACTG 5208 study participant samples were censored to include only one malaria diagnosis per patient; B) ACTG 5208 study participant samples to include multiple
episodes (only if separated by at least one malaria negative sample).
doi:10.1371/journal.pone.0034399.t002
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against malaria in HIV-infected populations, may have also
impacted our results by reducing the episodes of malaria. While
pharmacokinetic interactions are also possible when drugs are co-
administered, and are a particular concern with ritonavir, a drug
well known to affect the pharmacokinetics of many drugs including
antimalarials, an interaction of this drug with cotrimoxazole seems
unlikely to be an explanation for any lack or antimalarial effect
observed among subjects in the current study. Both groups
receiving cotrimoxazole, regardless of their ART treatment
regimen had reduced episodes of malaria (Table 2).
A pharmacodynamic interaction may be associated with the
inability of PI-based ART to protect the current cohort of women
from malaria infection. While the primary mode of action of
cotrimoxazole is understood, the antimalarial mode of action of
the PIs is still not known. A better understanding of the basis of the
antimalarial effect of PIs may enable prediction of clinically
significant pharmacodynamic interactions. Both cotrimoxazole
and individual PIs may also have off-target effects that alter the
activity of the other drug or additional drugs that may be used to
treat HIV-infected patients with opportunistic pathogens. These
interactions must be understood to ensure the use of the most
effective drug treatment regimens. The ability of the PIs to
modulate aspects of the immune system, decrease the expression of
CD36 and interfere with the phagocytosis of parasitized
erythrocytes [11], may also be associated with the inability of
LPV/r to provide antimalarial protection in the current study.
Indirect antimalarial benefits, that were not examined in this
study, including reduced cytoadherence [11] and decreased
gametocyte carriage [17] that may also be derived from PI-based
ART also need to be considered. Studies in children and pregnant
women, who are at greater risk of clinical malaria, also need to be
performed. Additionally, as laboratory studies suggest that the PIs
interact synergistically with selected antimalarial agents such as
chloroquine and mefloquine [18], the use of these combinations
warrants further investigation. These combinations may be
particularly useful against multi-drug resistant (MDR) parasites
given the ability of PIs to inhibit MDR pumps [19]. They may also
result in the boosting of drug levels due to cytochrome P450
interactions/competition [20].
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